Heavy/Light Chain Assay for Monitoring IgA Multiple Myeloma: Digging Out the IgA from the β Region.
Calderon B et al. Clin Chem. 2014 Dec 10. pii: clinchem.2014.234757. [Epub ahead of print].
Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Mithraprabhu S et al. Epigenetics. 2014 Dec 6:0. [Epub ahead of print].
Calorimetric markers of bence jones and nonsecretory multiple myeloma serum proteome.
Todinova S et al. Anal Chem. 2014 Dec 16;86(24):12355-61. doi: 10.1021/ac503677d. Epub 2014 Dec 5.
Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.
Shi Q et al. Cancer. 2014 Dec 2. doi: 10.1002/cncr.29154. [Epub ahead of print].
Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays.
Katzmann JA et al. Clin Chem. 2014 Dec 1. pii: clinchem.2014.231985. [Epub ahead of print].
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
Landgren O et al. Am J Hematol. 2014 Dec;89(12):1159-60. doi: 10.1002/ajh.23831.